- Joseph Eron, MD
- BI 1100-1452: A Case Control Toxicogenomics Study to Identify Unique Polymorphisms in Patients who have Experienced Symptomatic Hepatotoxicity or Severe Cutateous Toxicity Within the First 8 Weeks of Nevirapine Therapy
- Kristine Patterson , MD
- An Open-Label, Multi-center Trial to Compare the Efficacy, Safety and tolerability of Prezista-r by Gender and race when Adinistered in Combination with and Individually Optimized Regimen over a 48-week Treatment Period.
- David Wohl , MD
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Study Assessing the Safety and Efficacy of a 2mg Dose of TH9507, A Growth Hormone Reseasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
-
A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Verses Kaletra in HIV-Infected Patients Switched from a Stable Kaletra Based Regimen—Study B
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Extension Study Assessing the Efficacy and Long-Term Safety f a 2Mg Dose of TH9507, A Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat
|
